Fosamax for Male Osteoporosis: Off-Label Use, Evidence, and Monitoring

Is Fosamax FDA-Approved or Off-Label for Male Osteoporosis?

Alendronate received FDA approval specifically for the treatment of osteoporosis in men in 2000, making it one of the few bisphosphonates with an on-label male indication. The approved doses are 10 mg orally once daily or 70 mg orally once weekly. Prescribing alendronate to a man with osteoporosis is therefore not an off-label act, though many clinicians and patients still ask whether it is, because the drug is historically associated with postmenopausal women.

The confusion arises for two reasons. First, the original 1995 approval covered only postmenopausal women, and early marketing reflected that population. Second, certain related indications, such as using alendronate in men for glucocorticoid-induced osteoporosis or for osteopenia (T-score between -1.0 and -2.5) rather than frank osteoporosis, do carry off-label status and require a separate risk-benefit conversation. FDA labeling for alendronate sodium tablets specifies the approved populations explicitly.

How Male Osteoporosis Differs from Female Osteoporosis

Osteoporosis in men is both underdiagnosed and undertreated relative to the disease in women. Approximately 2 million men in the United States have osteoporosis, and another 12 million are estimated to have low bone mass, according to National Institutes of Health data. Men account for roughly 30% of all hip fractures, and 1-year mortality after a male hip fracture reaches 37%, compared with approximately 20% in women, per a population analysis published in JAMA.

Secondary causes drive male osteoporosis more often than primary age-related bone loss. Hypogonadism (testosterone deficiency), chronic glucocorticoid use, alcohol use disorder, and gastrointestinal malabsorption each lower bone mineral density independently. A workup that omits these diagnoses risks treating the symptom while missing the cause.

When Alendronate Is Genuinely Off-Label in Men

Three scenarios in men do fall outside the approved label:

1. Osteopenia without fracture history (T-score -1.0 to -2.5) when FRAX 10-year hip fracture probability is below the National Osteoporosis Foundation threshold of 3%
2. Glucocorticoid-induced bone loss in men, which has its own separate FDA-approved pathway for alendronate but is sometimes prescribed without following the specific glucocorticoid-induced osteoporosis dosing algorithm
3. Prevention (rather than treatment) in men, an indication that is FDA-approved only for postmenopausal women

Each of these scenarios requires documented shared decision-making and a FRAX calculation before prescribing.

Evidence Base: What Do the Clinical Trials Show?

The foundational trial for alendronate in men is the Orwoll et al. Randomized, double-blind, placebo-controlled study published in the New England Journal of Medicine in 2000. The trial enrolled 241 men aged 31 to 87 years with low bone mineral density (lumbar spine or femoral neck T-score at or below -2.0, or a prior vertebral fracture). After 2 years, men on alendronate 10 mg/day gained 7.1% lumbar spine BMD compared with 1.8% in the placebo group (P<0.001). Femoral neck BMD increased by 2.5% versus a 0.1% loss in placebo (P<0.001).

Fracture Outcomes in Men

Vertebral fracture incidence, a secondary endpoint in Orwoll et al., was reduced by 29% in the alendronate group compared with placebo over the 2-year follow-up period. The trial was not powered for hip fracture as a primary endpoint, so hip fracture data in men specifically remain limited compared with the large female trials such as FIT (Fracture Intervention Trial, N=6,459).

A meta-analysis by Nayak et al. Published in Annals of Internal Medicine pooled data from bisphosphonate trials in men and found a statistically significant reduction in morphometric vertebral fractures across the bisphosphonate class (relative risk 0.60, 95% CI 0.41 to 0.87). Alendronate drove the majority of person-years in that pooled analysis.

Long-Term Data: The FLEX Extension

The Fracture Intervention Trial Long-Term Extension (FLEX, N=1,099 postmenopausal women on prior alendronate) showed that 5 years of alendronate followed by a drug holiday preserved spine and hip BMD over 5 additional years compared with placebo discontinuation, with nonvertebral fracture rates remaining low in the continued-therapy group. Bone et al. Published FLEX in JAMA in 2004. While FLEX enrolled women, the pharmacodynamic mechanisms of bisphosphonate binding to hydroxyapatite are not sex-specific, and the 2023 Endocrine Society Clinical Practice Guideline on osteoporosis in men extrapolates FLEX data to male drug-holiday decisions at 3 to 5 years.

How Does Alendronate Compare with Other Options for Men?

Zoledronic acid (5 mg IV once yearly) is the other bisphosphonate with a male-specific FDA approval. The Lyles et al. HORIZON-Recurrent Fracture Trial (N=2,127, mixed sex) demonstrated a 35% reduction in new vertebral fractures with zoledronic acid versus placebo at 3 years, published in the New England Journal of Medicine. For men who cannot tolerate oral bisphosphonates due to esophageal disease or adherence issues, zoledronic acid becomes the preferred bisphosphonate. Teriparatide (20 mcg/day subcutaneous) and romosozumab are reserved for men with very high fracture risk or bisphosphonate failure, per Endocrine Society guidelines.

Dosing Alendronate in Men: Practical Prescribing Details

The two approved regimens are 10 mg once daily and 70 mg once weekly. The weekly tablet offers a significant adherence advantage. A crossover adherence trial by Cramer et al. showed that weekly dosing achieved a 12-month persistence rate of 56% versus 31% for daily dosing. Persistence matters clinically because each 1% decrease in medication possession ratio correlates with a measurable loss of BMD protection over a 2-year period.

Administration Rules That Determine Efficacy

Bioavailability of alendronate is only 0.6% under ideal conditions and falls to near zero when taken with food, coffee, or other medications. Men must take the tablet with 6 to 8 ounces of plain water, remain upright for at least 30 minutes, and eat nothing else for at least 30 minutes after the dose. The FDA prescribing information lists these as label requirements, not suggestions. Failure to follow these instructions is the most common reason for treatment non-response.

Calcium and Vitamin D Co-administration

Calcium and vitamin D supplementation is required alongside alendronate. The 2023 Endocrine Society guideline recommends 1,000 to 1,200 mg of elemental calcium per day (from diet and supplements combined) and 600 to 800 IU of vitamin D3 daily in men being treated for osteoporosis. Calcium taken within 2 hours of the alendronate dose will chelate the drug and reduce absorption, so the doses should be separated.

Renal Dosing Threshold

Alendronate should not be prescribed to men with a creatinine clearance below 35 mL/min. At this level of renal impairment, bisphosphonate accumulates in bone at concentrations not studied in clinical trials, and the risk profile shifts unfavorably. The FDA label contraindicates use below this threshold. Calculating an estimated glomerular filtration rate using the CKD-EPI equation before each prescription renewal is standard practice.

Monitoring Requirements for Men on Alendronate

Monitoring alendronate therapy in men involves four distinct domains: bone mineral density, biochemical markers of bone turnover, renal function, and surveillance for rare but serious adverse effects. The American College of Rheumatology and Endocrine Society guidelines align on most of these intervals.

DXA Scanning Schedule

Baseline DXA should cover the lumbar spine (L1-L4), total hip, and femoral neck before initiating therapy. A lateral vertebral assessment (LVA) at baseline identifies prevalent morphometric vertebral fractures that would otherwise go unrecognized and affect fracture risk classification. Repeat DXA is appropriate at 1 to 2 years after initiation to confirm a treatment response. Once BMD has stabilized, extending the interval to every 2 years is acceptable per NOF guidelines. A BMD decline of more than the least significant change (LSC) of the specific DXA machine, typically 2 to 4% at the spine and 3 to 6% at the hip, signals either non-adherence, secondary causes, or true treatment failure requiring medication change.

Biochemical Bone Turnover Markers

Serum C-terminal telopeptide of type I collagen (CTX) and procollagen type 1 N-terminal propeptide (P1NP) are the International Osteoporosis Foundation-endorsed reference markers for monitoring bisphosphonate therapy. CTX should fall by 50 to 70% from baseline within 3 to 6 months of starting alendronate. A CTX that remains elevated suggests non-adherence or malabsorption. Blood should be drawn fasting in the morning because CTX shows diurnal variation of up to 40%, with peak levels in the early morning hours. P1NP reflects bone formation and declines more slowly, typically reaching nadir at 6 to 12 months.

Renal and Metabolic Labs

Serum creatinine and calculated eGFR should be checked at baseline and at each annual visit or prescription renewal. Serum calcium, phosphate, and 25-hydroxyvitamin D levels at baseline identify hypocalcemia or vitamin D deficiency, both of which are relative contraindications to starting a bisphosphonate before correction. The Endocrine Society recommends correcting 25-OH vitamin D to above 30 ng/mL before initiating therapy to reduce the risk of hypocalcemia during the first weeks of treatment.

Dental and Musculoskeletal Surveillance

Osteonecrosis of the jaw (ONJ) affects fewer than 1 in 10,000 patients taking oral bisphosphonates for osteoporosis, a substantially lower rate than the 1 to 10% reported in oncology patients on high-dose intravenous bisphosphonates. The American Dental Association recommends a dental examination and completion of any invasive dental work before starting bisphosphonate therapy whenever possible, along with maintenance of good oral hygiene during treatment. Discontinuing alendronate before elective dental surgery remains controversial; the evidence does not support a mandatory drug holiday for routine extractions in low-risk patients.

Atypical femoral fractures (AFF) are stress fractures of the subtrochanteric or femoral shaft region associated with long-duration bisphosphonate use. The estimated incidence is 3.2 to 50 per 100,000 person-years, rising with treatment duration beyond 5 years, per an ASBMR task force report. Men who report new thigh or groin pain during bisphosphonate therapy should have plain radiographs of both femurs before any invasive procedures. The contralateral femur is also at risk and should be imaged.

The Drug Holiday: When to Stop and When to Restart

The drug holiday concept, stopping alendronate after a defined period while the drug's skeletal reservoir continues to provide some protection, applies to men who have achieved the treatment goal. The residency of alendronate in bone means antiresorptive effects persist for years after the last dose. A drug holiday is generally appropriate after 3 to 5 years if the hip T-score is above -2.5 and the man has not sustained a new fragility fracture during treatment.

The 2023 Endocrine Society guideline advises that men at high fracture risk, defined as a prior hip or spine fracture, a T-score below -2.5 at the hip, or a FRAX 10-year hip fracture probability above 3%, should continue bisphosphonate therapy beyond 5 years rather than taking a holiday. During any holiday, monitoring with DXA and CTX every 2 years identifies men who need to restart earlier than expected.

The following decision framework summarizes the HealthRX approach to the drug holiday decision in men on alendronate:

| Clinical scenario | Recommended action | |---|---| | Hip T-score above -2.5, no prior fracture, FRAX hip <3% after 3-5 years | Drug holiday; recheck DXA and CTX at 2 years | | Hip T-score -2.0 to -2.5, no prior fracture, FRAX hip 3-5% | Holiday with close monitoring; restart if T-score falls or CTX rises significantly | | Prior vertebral or hip fracture at any T-score | Continue therapy; reassess at year 6-10 | | T-score below -2.5 at hip at any point during treatment | Continue therapy indefinitely; reassess every 2 years | | New thigh pain during therapy | Stop, image bilateral femurs, evaluate for AFF before continuing |

Secondary Causes of Male Osteoporosis: What to Rule Out Before Prescribing

Starting alendronate in a man without investigating secondary causes of bone loss is incomplete care. Between 50 and 80% of men with osteoporosis have an identifiable contributing condition, compared with approximately 20 to 30% of women, per a review in the Journal of Clinical Endocrinology and Metabolism.

Essential Baseline Workup

The minimum workup before prescribing alendronate in a man includes:

• Serum testosterone (total and free) to evaluate for hypogonadism
• 24-hour urine calcium to identify hypercalciuria or malabsorption
• Serum protein electrophoresis (SPEP) to exclude multiple myeloma in men over 50
• TSH to rule out subclinical hyperthyroidism
• Serum PTH and calcium to exclude primary hyperparathyroidism
• 25-hydroxyvitamin D level
• Complete metabolic panel including creatinine and liver enzymes
• CBC to screen for hematologic malignancy

The Endocrine Society 2023 guideline explicitly states that testosterone replacement, when hypogonadism is confirmed, may itself increase BMD and should be considered alongside or before bisphosphonate therapy. A review in the Journal of Bone and Mineral Research found that testosterone therapy in hypogonadal men produced lumbar spine BMD gains of 5 to 8% over 2 years, suggesting that addressing the primary deficiency can meaningfully change the treatment calculus.

Glucocorticoid-Induced Osteoporosis in Men

Men on prednisone 5 mg/day or equivalent for 3 months or longer face accelerated bone loss. The American College of Rheumatology 2022 Guideline on glucocorticoid-induced osteoporosis conditionally recommends oral bisphosphonate therapy (alendronate or risedronate) as first-line in men aged 40 and over taking medium or high doses of glucocorticoids, using the FRAX calculator calibrated for glucocorticoid use. This is a separate, specific approved indication for alendronate and is not off-label when dosed and monitored per the ACR algorithm.

Adherence and Common Barriers in Men

Men adhere to osteoporosis medications at lower rates than women, in part because the disease has lower cultural salience in this population. A JAMA Internal Medicine analysis found that 1-year persistence with any oral bisphosphonate was 44% in men versus 52% in women across a Medicare claims sample of over 240,000 patients. Each percentage point drop in adherence correlated with a measurable loss of fracture protection.

Specific barriers include the strict fasting and posture requirements at dosing time, gastrointestinal side effects (esophageal irritation affects up to 15 to 20% of oral bisphosphonate users in open-label studies), and physician underestimation of male fracture risk. For men who develop upper GI intolerance, switching to the weekly effervescent formulation of alendronate or transitioning to annual intravenous zoledronic acid are the two most evidence-supported alternatives per Cochrane Review data on bisphosphonate adherence interventions.

The 2023 Endocrine Society clinical practice guideline states directly: "In men with osteoporosis, bisphosphonate therapy should be offered without delay after an osteoporotic fracture, given the high 1-year refracture risk." This guidance challenges the historical tendency to defer treatment in men pending more comprehensive secondary evaluations.

Practical Prescribing Checklist for Men Starting Alendronate

Before the first prescription:

• Confirm diagnosis: DXA T-score at or below -2.5 at spine or hip, or fragility fracture regardless of T-score
• Complete secondary cause workup (see above)
• Correct vitamin D deficiency and hypocalcemia
• Check eGFR; do not prescribe if <35 mL/min
• Dental exam and completion of pending invasive dental work
• FRAX calculation to document fracture risk and support prescribing rationale
• Document informed consent covering ONJ, AFF, esophageal risks, and the monitoring schedule

At initiation:

• Prescribe 70 mg once weekly (preferred for adherence) or 10 mg daily
• Co-prescribe calcium 500 to 600 mg twice daily (if dietary intake is below 1,000 mg/day) and vitamin D3 600 to 800 IU daily
• Provide written administration instructions with explicit fasting and posture guidance

At 3 to 6 months:

• Fasting morning CTX to confirm biochemical response (target 50 to 70% reduction from baseline)
• Review tolerability and adherence

At 1 to 2 years:

• Repeat DXA at spine and hip; compare to baseline using the same machine when possible
• Repeat 25-OH vitamin D and serum calcium
• Recalculate eGFR
• Review ongoing indications and fracture risk to determine whether to continue, switch, or plan a drug holiday

After year 3 to 5:

• Apply the drug holiday decision framework above
• If continuing beyond 5 years, reimage femurs (plain X-ray or MRI of both hips) to screen for asymptomatic atypical femoral fracture stress reactions, as recommended by ASBMR task force data

The CTX target of 50 to 70% below the individual patient baseline remains the most actionable single number in alendronate monitoring for men.